Storys zum Thema Medizinische Behandlung

Debiopharm International SA

DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS

Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...

HUMA Therapeutics

Huma to provide best-in-class digital clinical trials solutions through landmark acquisition of Alcedis

London and Frankfurt, Germany (ots/PRNewswire) - - Acquisition combines award-winning digital health platform with global clinical research expertise acquired over 25 years - Creates new and advanced digital solutions across all phases of clinical trials - Accelerates patient recruitment and the development of new ...

Menarini-Silicon Biosystems

Circulating Tumor Cell detection by Menarini Group's CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease

Huntingdon Valley, Pa. (ots/PRNewswire) - Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems' CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with ...

Acousia Therapeutics GmbH

Hearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule

Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical ...

REVEAL GENOMICS, S.L.

REVEAL GENOMICS PRESENTS THE LATEST HER2DX® DATA IN HER2+ BREAST CANCER AT SABCS 2022

San Antonio (ots/PRNewswire) - - The HER2DX® risk score predicted long-term survival outcomes in clinically low-risk patients in APT and ATEMPT clinical trials. - The HER2DX® pCR score predicted response to chemotherapy in combination with trastuzumab and pertuzumab in DAPHNe and GOM clinical trials. - HER2DX®️ is the first genomic test in the world specialized in ...

TauRx Pharmaceuticals Ltd

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference ...

Acousia Therapeutics GmbH

Hearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11–15

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen), will present data on its lead candidates — clinical stage ACOU085 and late ...

Schweizerischer Nationalfonds / Fonds national suisse

Improving the efficacy of antibiotics and curbing resistance

Bern (ots) - New findings from NRP 72, financed by the Swiss National Science Foundation, are helping to curb antibiotic resistance. In the field of new antibiotics, however, structures needed for translating results into practice are lacking. Worldwide, more and more pathogens are becoming resistant to today's antibiotics. As antibiotics lose their efficacy, infections that were once easy to treat can give rise to fatal ...

TauRx Pharmaceuticals Ltd

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results

Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability - Shareholder ...

TauRx Pharmaceuticals Ltd

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results

Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability - Shareholder ...

Medison Pharma

Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America

Petach Tikvah, Israel (ots/PRNewswire) - With this latest expansion, Medison's global footprint is now extended across Israel, Central and Eastern Europe, Canada, Asia-Pacific and Latin America, offering patients in international markets improved access to highly innovative therapies. Medison Pharma ("Medison"), a global pharma company focused on providing access to ...

TES Pharma

TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis

Perugia, Italy (ots/PRNewswire) - INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal models TES Pharma is dedicated to the identification of novel therapeutic targets and ...

The International Osteoporosis Foundation (IOF)

On World Osteoporosis Day, take five steps to better bone health

Menarini-Silicon Biosystems

Menarini Silicon Biosystems's CELLSEARCH® CMMC and HER2-CTC Liquid Biopsy Tests obtain Reimbursement Codes with Preliminary Pricing Determination

Huntingdon Valley, Pa. (ots/PRNewswire) - These new codes are required to access Medicare/Medicaid insurance reimbursement for novel CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) and HER2 Circulating Tumor Cell (CTC-HER2) assays, to monitor disease status in patients with life-threatening illnesses. Menarini ...

Pharming Group N.V.

Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib

Leiden, Netherlands (ots/PRNewswire) - Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency This submission follows the grant of accelerated assessment allowing an expedited review for leniolisib from a standard 210 days ...

Evonik Industries AG

Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan

Essen, Germany (ots/PRNewswire) - - Evonik to produce commercial quantities of the drug substance vonoprazan for use in VOQUEZNA™ TRIPLE PAK™ and DUAL PAK™, and other products containing vonoprazan - Supply security through production at sites in Europe and North America - Agreement strengthens Evonik's track record as leading contract development and ...

Synapse Medicine

Synapse Medicine Initiates Multi-Site Implementation Study with Leading U.S Hospitals

New York (ots/PRNewswire) - - Synapse Medicine clinical decision support technology analyzes drug-related risks based on each patient's clinical characteristics and will be studied for its impact on inpatient pharmacist efficacy and efficiency. - The Synapse Medicine medication reconciliation tool will be deployed through an integration with the hospitals' current EPIC ...

Debiopharm International SA

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Lausanne, Switzerland (ots) - Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay ...

PHARMANOVIA

PHARMANOVIA ENTERS EXCLUSIVE LICENSING COLLABORATION FOR DIAZEPAM BUCCAL FILM

London (ots/PRNewswire) - - PHARMANOVIA EXCLUSIVELY LICENCES RIGHTS FOR A NOVEL WAY OF TREATING ACUTE EPILEPSY SEIZURE CLUSTERS IN EUROPE, MIDDLE EAST AND NORTH AFRICA - PATENTED BUCCAL FILM TECHNOLOGY HAS THE POTENTIAL TO IMPROVE THE EASE OF ADMINISTRATION FOR CAREGIVERS, PATIENTS AND HCPs Pharmanovia, the lifecycle management company, has today announced that it has ...

Debiopharm International SA

BIG IMPACT, SMALL PACKAGE: DEBIOPHARM LAUNCHES A WAZOKU OPEN-INNOVATION CHALLENGE FOR SMALL ANTIBODY DRUG CONJUGATE TECHNOLOGY

Lausanne, Switzerland (ots) - · Currently approved Antibody-Drug Conjugates (ADCs) are large molecules (150 kDa) composed of an antibody, a cytotoxic payload, and a linker connecting the two precedent elements · Debiopharm has launched an ADC Innovation Challenge to a pool of international “problem Solvers” ...

Guerbet

Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)

Villepinte, France (ots/PRNewswire) - - FDA approval of Elucirem™ (NDA 216986) was granted after priority review, a designation assigned to applications for drugs that provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions compared to available therapies. - In the approved indications, a ...

MC2 Therapeutics

MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

Copenhagen, Denmark (ots/PRNewswire) - - Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated skin diseases - First patients dosed in Europe in Phase 2 trial assessing the safety and efficacy of MC2-25 Cream in Chronic Kidney Disease-associated Pruritus (CKD-aP) stages 3-5 patients - MC2-25 Cream has the potential to become ...

MC2 Therapeutics

MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

Copenhagen, Denmark (ots/PRNewswire) - - Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated skin diseases - First patients dosed in Europe in Phase 2 trial assessing the safety and efficacy of MC2-25 Cream in Chronic Kidney Disease-associated Pruritus (CKD-aP) stages 3-5 patients - MC2-25 Cream has the potential to become ...

European Society for Medical Oncology (ESMO)

ESMO 2022 - Great oaks grow from small acorns: oncology is committed to doing its part for sustainability

Paris (ots) - At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in Europe, which has gathered 28k participants from 167 countries, many discussions will be around sustainability, prevention and novel approaches which could soon become a reality in the clinic. - Late-breaking results elucidate ...